Eos puts new gerotherapeutic to the test in aging mice
Berlin keynote details Eos SENOLYTIX’s pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan. A 167-week-old mouse makes an unlikely but persuasive ambassador for geroscience, particularly when he appears to be moving around with considerably more energy than
<p>Berlin keynote details Eos SENOLYTIX’s pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan. A 167-week-old mouse makes an unlikely but persuasive ambassador for geroscience, particularly when he appears to be moving around with considerably more energy than </p>